PULMATRIX, INC. (NASDAQ:PULM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On June13, 2017 (the Effective Date), Amit Munshi was appointed
as a Class I director of the board of directors (the Board) and a
member of the audit committee of Pulmatrix, Inc. (the Company),
to serve for a term expiring at the next annual meeting of the
Companys stockholders at which the term of the Class I directors
expires or until his successor is duly elected and qualified, or
his earlier death, resignation or removal.
In connection with his appointment to the Board, Mr.Munchi was
granted a stock option on the Effective Date to purchase 8,800
shares of the Companys common stock, par value $0.0001 per share
(the Common Stock) with (i)an exercise price equal to the fair
market value of a share of Common Stock on the date of grant,
(ii)a term of ten years and (iii)one-fourth of the stock option
vesting on the first anniversary of the date of grant and an
additional 2.083% vesting on the last day of each of the
thirty-six months that follow the first anniversary of the date
of grant, provided that Mr.Munshi is providing services to the
Company through the applicable vesting dates and subject to the
terms and conditions of the Pulmatrix, Inc. 2013 Employee,
Director and Consultant Equity Incentive Plan and the Companys
standard form of stock option agreement.
| Item8.01 | Other Events. |
On June15, 2017, the Company issued a press release announcing
the appointment of Mr.Munshi to the Board.A copy of the press
release is attached as Exhibit 99.1 to this Current Report on
Form 8-K and is incorporated herein by reference.
| Item9.01 | Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit Number |
Description |
|
| 99.1 | Press Release dated June 15, 2017. |
About PULMATRIX, INC. (NASDAQ:PULM)
Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.